AstraZeneca taps New Jersey firm to manufacture Covid-19 vaccine candidate
New Jersey-based Catalent Inc. took over a large contract drug manufacturing facility in Maryland when it acquired Paragon Bioservices for $1.2 billion in 2019.
Source link